PET/CT Imaging for Kidney Cancer
Trial Summary
What is the purpose of this trial?
Staging of kidney cancer is primarily achieved by computerized tomography (CT) scans or magnetic resonance imaging (MRI). If a patient is found to have limited metastatic disease, surgical removal or radiation therapy could be considered in order to control the majority of the disease. However, if metastases are more widespread, systemic (drug) therapy may be the preferred management option. The identification of additional metastatic sites using more sensitive imaging modalities therefore has the potential to alter management, and this remains an unmet need in the field. This study will investigate the utility of positron emission tomography (PET) imaging with PSMA (prostate specific membrane antigen). Kidney cancer of the clear cell subtype has demonstrated high expression of PSMA, making it a disease in which PSMA-targeted PET imaging could help to identify occult metastatic disease.
Will I have to stop taking my current medications?
The trial protocol does not specify whether you need to stop taking your current medications. It is best to discuss this with the trial coordinators or your doctor.
What data supports the effectiveness of the treatment [18F] PSMA-1007 PET/CT for kidney cancer?
Research shows that [18F] PSMA-1007 PET/CT can effectively highlight kidney tumors and lung nodules, providing valuable information about the type and stage of kidney cancer. This imaging method is promising for understanding and planning treatment for kidney cancer, similar to its use in prostate cancer.12345
Is 18F-PSMA-1007 PET/CT safe for humans?
How does PET/CT imaging differ from other treatments for kidney cancer?
PET/CT imaging for kidney cancer is unique because it uses a special tracer that targets prostate-specific membrane antigen (PSMA), which is also present in the blood vessels of kidney tumors. This imaging method can provide detailed information about the tumor's type and stage, which is not typically available with standard imaging techniques.12349
Research Team
Melissa Huynh, MD
Principal Investigator
Western University
Eligibility Criteria
This trial is for individuals with metastatic clear cell renal cell carcinoma. It's designed to see if a new type of PET/CT scan can find hidden cancer spread better than current methods.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Imaging and Baseline Assessment
Participants undergo baseline conventional imaging and [18F] PSMA-1007 PET/CT to identify metastatic lesions
Follow-up
Participants are monitored for changes in management based on imaging results
Treatment Details
Interventions
- [18F] PSMA-1007 PET/CT (Procedure)
Find a Clinic Near You
Who Is Running the Clinical Trial?
Western University
Lead Sponsor